|
US479739A
(en)
*
|
|
1892-07-26 |
|
dimond |
|
US3096248A
(en)
*
|
1959-04-06 |
1963-07-02 |
Rexall Drug & Chemical Company |
Method of making an encapsulated tablet
|
|
US3406178A
(en)
|
1964-02-04 |
1968-10-15 |
Monsanto Chem Australia Ltd |
Preparation of 2-substituted benzimidazoles
|
|
US3362956A
(en)
|
1965-08-19 |
1968-01-09 |
Sterling Drug Inc |
1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
|
|
US4200641A
(en)
|
1976-12-21 |
1980-04-29 |
Janssen Pharmaceutica, N.V. |
1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives
|
|
DK251079A
(da)
|
1978-06-20 |
1979-12-21 |
Synthelabo |
Fremgangsmaade til fremstilling af phenylpiperazinderivater
|
|
DE3000979A1
(de)
*
|
1980-01-12 |
1981-07-23 |
Dr. Karl Thomae Gmbh, 7950 Biberach |
Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
|
|
DE3126703A1
(de)
|
1981-07-07 |
1983-01-27 |
Dr. Karl Thomae Gmbh, 7950 Biberach |
Bromhexin-retardform und verfahren zu ihrer herstellung
|
|
JPS58134033A
(ja)
|
1982-02-02 |
1983-08-10 |
Fujisawa Pharmaceut Co Ltd |
医薬組成物
|
|
IT1176613B
(it)
|
1984-08-14 |
1987-08-18 |
Ravizza Spa |
Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
|
|
IE58370B1
(en)
|
1985-04-10 |
1993-09-08 |
Lundbeck & Co As H |
Indole derivatives
|
|
GB8607294D0
(en)
|
1985-04-17 |
1986-04-30 |
Ici America Inc |
Heterocyclic amide derivatives
|
|
NL8601494A
(nl)
|
1985-06-22 |
1987-01-16 |
Sandoz Ag |
Thiazolen, hun bereiding en farmaceutische preparaten die ze bevatten.
|
|
DE3620643A1
(de)
|
1985-06-22 |
1987-01-22 |
Sandoz Ag |
Thiazole, ihre herstellung und verwendung
|
|
GB8601160D0
(en)
|
1986-01-17 |
1986-02-19 |
Fujisawa Pharmaceutical Co |
Heterocyclic compounds
|
|
US5036088A
(en)
|
1986-06-09 |
1991-07-30 |
Pfizer Inc. |
Antiallergy and antiinflammatory agents, compositions and use
|
|
JPH0784462B2
(ja)
|
1986-07-25 |
1995-09-13 |
日清製粉株式会社 |
ベンゾイミダゾ−ル誘導体
|
|
US4968508A
(en)
*
|
1987-02-27 |
1990-11-06 |
Eli Lilly And Company |
Sustained release matrix
|
|
US4792452A
(en)
*
|
1987-07-28 |
1988-12-20 |
E. R. Squibb & Sons, Inc. |
Controlled release formulation
|
|
GB8830312D0
(en)
|
1988-12-28 |
1989-02-22 |
Lundbeck & Co As H |
Heterocyclic compounds
|
|
US4954503A
(en)
|
1989-09-11 |
1990-09-04 |
Hoechst-Roussel Pharmaceuticals, Inc. |
3-(1-substituted-4-piperazinyl)-1H-indazoles
|
|
IE912826A1
(en)
|
1990-08-09 |
1992-02-12 |
Massachusetts Inst Technology |
Method for treating the premenstrual or late luteal phase¹syndrome
|
|
EP0497985B1
(en)
|
1990-08-24 |
1998-07-22 |
Shin-Etsu Chemical Co., Ltd. |
Coating base for pharmaceutical film and production thereof
|
|
NZ241613A
(en)
*
|
1991-02-27 |
1993-06-25 |
Janssen Pharmaceutica Nv |
Highlighting intagliations in tablets
|
|
SE9100860D0
(sv)
*
|
1991-03-22 |
1991-03-22 |
Kabi Pharmacia Ab |
New use
|
|
FR2675800A1
(fr)
|
1991-04-26 |
1992-10-30 |
Rhone Poulenc Rorer Sa |
Derives heterocycliques antiserotonines leur preparation et les medicaments les contenant.
|
|
WO1992019595A1
(en)
|
1991-05-07 |
1992-11-12 |
Merck & Co., Inc. |
Fibrinogen receptor antagonists
|
|
US5407686A
(en)
*
|
1991-11-27 |
1995-04-18 |
Sidmak Laboratories, Inc. |
Sustained release composition for oral administration of active ingredient
|
|
DE4216364A1
(de)
|
1991-12-14 |
1993-11-25 |
Thomae Gmbh Dr K |
Neue Pyridylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
|
US5225417A
(en)
*
|
1992-01-21 |
1993-07-06 |
G. D. Searle & Co. |
Opioid agonist compounds
|
|
US5492907A
(en)
*
|
1992-12-09 |
1996-02-20 |
The United States Of America As Represented By The Department Of Health & Human Services |
Antipsychotic composition and method of treatment
|
|
DE69429768T2
(de)
|
1993-04-05 |
2002-09-19 |
Competitive Technologies, Inc. |
Diagnose und behandlung von erektilen funktionsstörungen
|
|
FR2707294B1
(fr)
|
1993-07-06 |
1995-09-29 |
Pf Medicament |
Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine.
|
|
GB9401090D0
(en)
|
1994-01-21 |
1994-03-16 |
Glaxo Lab Sa |
Chemical compounds
|
|
JP2860604B2
(ja)
|
1994-06-14 |
1999-02-24 |
ファイザー インク． |
中枢ドーパミン作動活性を有するベンズイミダゾロン誘導体
|
|
CZ287558B6
(en)
|
1994-08-23 |
2000-12-13 |
Smithkline Beecham Plc |
Pharmaceutical preparation
|
|
DE69531476T2
(de)
|
1994-09-12 |
2004-06-09 |
Lilly Industries Ltd., Basingstoke |
Serotonergische Modulatoren
|
|
JPH08143476A
(ja)
|
1994-11-18 |
1996-06-04 |
Japan Tobacco Inc |
薬物放出制御膜及び固形製剤
|
|
FR2727682A1
(fr)
*
|
1994-12-02 |
1996-06-07 |
Pf Medicament |
Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
|
|
US5552412A
(en)
*
|
1995-01-09 |
1996-09-03 |
Pfizer Inc |
5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
|
|
US5883094A
(en)
|
1995-04-24 |
1999-03-16 |
Pfizer Inc. |
Benzimidazolone derivatives with central dopaminergic activity
|
|
US5854290A
(en)
*
|
1995-09-21 |
1998-12-29 |
Amy F. T. Arnsten |
Use of guanfacine in the treatment of behavioral disorders
|
|
US6083947A
(en)
*
|
1996-01-29 |
2000-07-04 |
The Regents Of The University Of California |
Method for treating sexual dysfunctions
|
|
GB9613423D0
(en)
|
1996-06-26 |
1996-08-28 |
Lilly Industries Ltd |
Pharmaceutical compounds
|
|
US5916916A
(en)
*
|
1996-10-10 |
1999-06-29 |
Eli Lilly And Company |
1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
|
|
ZA979937B
(en)
|
1996-11-06 |
1999-05-18 |
Sharmatek Inc |
Delayed delivery system for acid-sensitive drugs
|
|
CA2273351A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating sexual dysfunction
|
|
US5859246A
(en)
|
1997-01-30 |
1999-01-12 |
Neurogen Corporation |
1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands
|
|
US20040023948A1
(en)
*
|
1997-03-24 |
2004-02-05 |
Green Richard David |
Fast-dispersing dosage form containing 5-HT1 agonists
|
|
GB9706089D0
(en)
|
1997-03-24 |
1997-05-14 |
Scherer Ltd R P |
Pharmaceutical composition
|
|
CA2293815C
(en)
*
|
1997-06-11 |
2004-06-29 |
The Procter & Gamble Company |
Film-coated tablet for improved upper gastrointestinal tract safety
|
|
ATE241341T1
(de)
*
|
1997-09-10 |
2003-06-15 |
Takeda Chemical Industries Ltd |
Stabilisierte pharmazeutische zusammensetzung
|
|
SE9703375D0
(sv)
|
1997-09-18 |
1997-09-18 |
Astra Ab |
A new combination
|
|
CH692199A8
(fr)
*
|
1997-10-09 |
2002-06-14 |
Cermol S.A. |
Composes pyridiques et compositions pharmaceutique
|
|
JP3724157B2
(ja)
*
|
1997-10-30 |
2005-12-07 |
コニカミノルタホールディングス株式会社 |
映像観察装置
|
|
FR2775188B1
(fr)
*
|
1998-02-23 |
2001-03-09 |
Lipha |
Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
|
|
WO1999059584A1
(en)
|
1998-05-20 |
1999-11-25 |
Schering Corporation |
Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
|
|
AU3891299A
(en)
|
1998-05-21 |
1999-12-06 |
Eli Lilly And Company |
Combination therapy for treatment of depression
|
|
US20020151543A1
(en)
*
|
1998-05-28 |
2002-10-17 |
Sepracor Inc. |
Compositions and methods employing R (-) fluoxetine and other active ingredients
|
|
EP1085869A4
(en)
|
1998-06-11 |
2001-10-04 |
Merck & Co Inc |
Spiropiperidine derivatives as melanocortin receptor agonists
|
|
US6068846A
(en)
*
|
1998-08-05 |
2000-05-30 |
Melaleuca, Incorporated |
Methods and materials for treating depression and mood disorder
|
|
EP0982030A3
(en)
|
1998-08-17 |
2000-05-10 |
Pfizer Products Inc. |
2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands
|
|
UA67802C2
(uk)
|
1998-10-23 |
2004-07-15 |
Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. |
Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
|
|
WO2000028993A1
(en)
*
|
1998-11-19 |
2000-05-25 |
Nortran Pharmaceuticals, Inc. |
Serotonin ligands as pro-erectile compounds
|
|
US6680071B1
(en)
*
|
1999-03-03 |
2004-01-20 |
R. P. Scherer Technologies, Inc. |
Opioid agonist in a fast dispersing dosage form
|
|
WO2000063193A1
(en)
|
1999-04-16 |
2000-10-26 |
Dr. Reddy's Research Foundation |
Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
|
|
AU5259100A
(en)
|
1999-04-28 |
2000-11-10 |
Respiratorius Ab |
Medicament
|
|
IT1312310B1
(it)
|
1999-05-07 |
2002-04-15 |
Recordati Ind Chimica E Farma |
Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
|
|
US6579968B1
(en)
|
1999-06-29 |
2003-06-17 |
Palatin Technologies, Inc. |
Compositions and methods for treatment of sexual dysfunction
|
|
US20030055070A1
(en)
|
1999-07-01 |
2003-03-20 |
Wilma Harrison |
Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction
|
|
US6346548B1
(en)
*
|
1999-08-16 |
2002-02-12 |
Cephalon, Inc. |
Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
|
|
DE19961334A1
(de)
|
1999-12-17 |
2001-06-21 |
Roehm Gmbh |
Spritzgußverfahren für neutrale und säuregruppenhaltige (Meth)acrylat-Copolymere
|
|
CN1396829A
(zh)
*
|
2000-02-24 |
2003-02-12 |
法玛西雅厄普约翰美国公司 |
新的药物联合形式
|
|
IL152781A0
(en)
|
2000-06-28 |
2003-06-24 |
Pfizer Prod Inc |
Melanocortin receptor ligands
|
|
US6960597B2
(en)
|
2000-06-30 |
2005-11-01 |
Orth-Mcneil Pharmaceutical, Inc. |
Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
|
|
US20020052370A1
(en)
|
2000-07-06 |
2002-05-02 |
Barber Christopher Gordon |
Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
|
|
US20040198706A1
(en)
|
2003-03-11 |
2004-10-07 |
Carrara Dario Norberto R. |
Methods and formulations for transdermal or transmucosal application of active agents
|
|
US6586435B2
(en)
|
2000-09-19 |
2003-07-01 |
Boehringer Ingelheim Pharma Kg |
Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
|
|
US6521623B1
(en)
|
2000-09-19 |
2003-02-18 |
Boehringer Ingelheim Pharma Kg |
N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
|
|
CA2417081C
(en)
|
2000-09-19 |
2008-08-05 |
Enzo Cereda |
New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
|
|
AU2001293804A1
(en)
|
2000-09-19 |
2002-04-02 |
Boehringer Ingelheim Pharma Kg |
New benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
|
|
AU2689502A
(en)
|
2000-11-22 |
2002-06-03 |
Abbott Lab |
The use of selective dopamine d4 receptor agonists for treating sexual dysfunction
|
|
GB0105893D0
(en)
|
2001-03-09 |
2001-04-25 |
Pfizer Ltd |
Pharmaceutically active compounds
|
|
GB0106446D0
(en)
|
2001-03-15 |
2001-05-02 |
Vernalis Res Ltd |
Chemical compounds
|
|
MXPA03006597A
(es)
|
2001-03-28 |
2004-10-15 |
Pfizer |
Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad.
|
|
PT1256343E
(pt)
|
2001-05-11 |
2006-11-30 |
Jurgen K Beck |
Flibaserina para o tratamento de perturbações do movimento extrapiramidais
|
|
US6627646B2
(en)
*
|
2001-07-17 |
2003-09-30 |
Sepracor Inc. |
Norastemizole polymorphs
|
|
CA2453609C
(en)
|
2001-07-18 |
2010-05-04 |
Merck & Co., Inc. |
Bridged piperidine derivatives as melanocortin receptor agonists
|
|
DE60231070D1
(de)
|
2001-07-30 |
2009-03-19 |
Spectrum Pharmaceuticals Inc |
Arylpiperazin gebundene Purinderivate
|
|
US7183410B2
(en)
|
2001-08-02 |
2007-02-27 |
Bidachem S.P.A. |
Stable polymorph of flibanserin
|
|
EP1414816B1
(en)
|
2001-08-02 |
2005-02-09 |
BIDACHEM S.p.A. |
Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
|
|
US20030060475A1
(en)
*
|
2001-08-10 |
2003-03-27 |
Boehringer Ingelheim Pharma Kg |
Method of using flibanserin for neuroprotection
|
|
DE10138273A1
(de)
|
2001-08-10 |
2003-02-27 |
Boehringer Ingelheim Pharma |
Arzneimittel mit neuroprotektiver Wirkung
|
|
HUP0202719A3
(en)
|
2001-08-21 |
2006-01-30 |
Pfizer Prod Inc |
Pharmaceutical compositions for the treatment of female sexual dysfunctions
|
|
DE10149674A1
(de)
*
|
2001-10-09 |
2003-04-24 |
Apogepha Arzneimittel Gmbh |
Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
|
|
UA78974C2
(en)
|
2001-10-20 |
2007-05-10 |
Boehringer Ingelheim Pharma |
Use of flibanserin for treating disorders of sexual desire
|
|
DE10209982A1
(de)
|
2002-03-07 |
2003-09-25 |
Boehringer Ingelheim Pharma |
Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
|
|
WO2003097058A1
(en)
|
2002-05-22 |
2003-11-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New pharmaceutical compositions containing flibanserin polymorph a
|
|
US20040048877A1
(en)
*
|
2002-05-22 |
2004-03-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions containing flibanserin
|
|
AU2003268026A1
(en)
|
2002-07-30 |
2004-02-16 |
Peter Migaly |
Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
|
|
US20040116532A1
(en)
*
|
2002-09-13 |
2004-06-17 |
Craig Heacock |
Pharmaceutical formulations of modafinil
|
|
US20040132697A1
(en)
*
|
2002-11-06 |
2004-07-08 |
Pfizer Inc. |
Treatment of female sexual dysfunction
|
|
GB0225908D0
(en)
|
2002-11-06 |
2002-12-11 |
Pfizer Ltd |
Treatment of female sexual dysfunction
|
|
US20040147581A1
(en)
*
|
2002-11-18 |
2004-07-29 |
Pharmacia Corporation |
Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
|
|
US20040193452A1
(en)
*
|
2003-01-06 |
2004-09-30 |
Laura Berman |
Method and system for computerized sexual function assessment of female users
|
|
WO2004069339A1
(en)
|
2003-01-29 |
2004-08-19 |
Psychogenics Inc. |
Treatment for attention-deficit hyperactivity disorder
|
|
US20050037983A1
(en)
|
2003-03-11 |
2005-02-17 |
Timothy Dinan |
Compositions and methods for the treatment of depression and other affective disorders
|
|
JP2007516949A
(ja)
|
2003-07-16 |
2007-06-28 |
ファイザー・インク |
性機能不全の治療
|
|
US20050065158A1
(en)
|
2003-07-16 |
2005-03-24 |
Pfizer Inc. |
Treatment of sexual dysfunction
|
|
EP1510133A1
(en)
*
|
2003-09-01 |
2005-03-02 |
Belovo S.A., Egg Science & Technology |
Balanced oil composition
|
|
NZ545884A
(en)
|
2003-09-11 |
2010-01-29 |
Xenoport Inc |
Treating and/or preventing urinary incontinence using prodrugs of GABA analogs
|
|
WO2005044238A1
(en)
|
2003-11-07 |
2005-05-19 |
Ranbaxy Laboratories Limited |
Modified release solid dosage form of amphetamine salts
|
|
US20050239798A1
(en)
|
2004-04-22 |
2005-10-27 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Method for the treatment of premenstrual and other female sexual disorders
|
|
MXPA06012059A
(es)
|
2004-04-22 |
2007-01-25 |
Boehringer Ingelheim Int |
Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii.
|
|
US20060014757A1
(en)
|
2004-07-14 |
2006-01-19 |
Boehringer Ingelheim Pharmaceuticals |
Method for the treatment of anorexia nervosa
|
|
US20060025420A1
(en)
|
2004-07-30 |
2006-02-02 |
Boehringer Ingelheimn International GmbH |
Pharmaceutical compositions for the treatment of female sexual disorders
|
|
JP2008511569A
(ja)
*
|
2004-09-03 |
2008-04-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
注意欠如活動過多障害の治療方法
|
|
JP2008516909A
(ja)
|
2004-10-18 |
2008-05-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
前立腺及び下部泌尿生殖路の病気を治療するためのβ−３アゴニストの使用
|
|
CA2599937A1
(en)
*
|
2005-03-04 |
2006-09-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
|
|
WO2006096439A2
(en)
*
|
2005-03-04 |
2006-09-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
|
|
JP2008538741A
(ja)
*
|
2005-03-04 |
2008-11-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
鬱病の治療用及び／又は予防用の医薬組成物
|
|
EP1904182A2
(en)
*
|
2005-05-06 |
2008-04-02 |
Boehringer Ingelheim International GmbH |
Method for the treatment of drug abuse with flibanserin
|
|
US20060258640A1
(en)
*
|
2005-05-13 |
2006-11-16 |
Boehringer Ingelheim International Gmbh |
Use of Flibanserin in the treatment of chronic pain
|
|
WO2006125042A1
(en)
*
|
2005-05-19 |
2006-11-23 |
Boehringer Ingelheim International Gmbh |
Method for the treatment of drug-induced sexual dysfunction
|
|
WO2006125041A1
(en)
|
2005-05-19 |
2006-11-23 |
Boehringer Ingelheim International Gmbh |
Method for the treatment of sexual dysfunctions due to medical conditions
|
|
US7884136B2
(en)
|
2005-06-27 |
2011-02-08 |
Biovail Laboratories International S.R.L. |
Modified-release formulations of a bupropion salt
|
|
PL1912650T3
(pl)
|
2005-08-03 |
2018-01-31 |
Sprout Pharmaceuticals Inc |
Zastosowanie flibanseryny w leczeniu otyłości
|
|
US8457162B2
(en)
|
2005-08-16 |
2013-06-04 |
Realtek Semiconductor Corp. |
Packet detection
|
|
HU227490B1
(en)
|
2005-08-26 |
2011-07-28 |
Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag |
Sustained release pharmaceutical preparation containing carvedilol
|
|
EP1940357A2
(en)
|
2005-09-30 |
2008-07-09 |
SmithKline Beecham Corporation |
Pharmaceutical compositions
|
|
US20070123540A1
(en)
*
|
2005-10-29 |
2007-05-31 |
Angelo Ceci |
Sexual desire enhancing medicaments comprising benzimidazolone derivatives
|
|
EP1945214A1
(en)
|
2005-10-29 |
2008-07-23 |
Boehringer Ingelheim International GmbH |
Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
|
|
US20070105869A1
(en)
|
2005-11-08 |
2007-05-10 |
Stephane Pollentier |
Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
|
|
AU2007211101B2
(en)
|
2006-01-27 |
2013-05-02 |
Adare Pharmaceuticals, Inc. |
Drug delivery systems comprising weakly basic drugs and organic acids
|
|
US20090023712A1
(en)
*
|
2006-02-18 |
2009-01-22 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin
|
|
JP2009527525A
(ja)
*
|
2006-02-20 |
2009-07-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
尿失禁治療用のベンゾイミダゾロン誘導体
|
|
WO2007099070A1
(en)
*
|
2006-02-28 |
2007-09-07 |
Boehringer Ingelheim International Gmbh |
Treatment of prevention of valvular heart disease with flibanserin
|
|
WO2007128802A2
(en)
|
2006-05-09 |
2007-11-15 |
Boehringer Ingelheim International Gmbh |
Use of flibanserin for the treatment of post-menopausal sexual desire disorders
|
|
DE602007004615D1
(de)
|
2006-06-30 |
2010-03-18 |
Boehringer Ingelheim Pharma |
Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
|
|
WO2008006839A2
(en)
|
2006-07-14 |
2008-01-17 |
Boehringer Ingelheim International Gmbh |
Combinations of flibanserin with caffeine, process for their preparation and use thereof as medicaments
|
|
US20090318469A1
(en)
|
2006-07-14 |
2009-12-24 |
Boehringer Ingelheim International Gmbh |
Use of Flibanserin for the Treatment of Sexual Disorders in Females
|
|
MX2009001551A
(es)
|
2006-08-14 |
2009-02-20 |
Boehringer Ingelheim Int |
Formulaciones de flibanserina y metodo para fabricarlas.
|
|
CL2007002214A1
(es)
*
|
2006-08-14 |
2008-03-07 |
Boehringer Ingelheim Int |
Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
|
|
MX2009002031A
(es)
|
2006-08-25 |
2009-03-06 |
Boehringer Ingelheim Int |
Sistema de liberacion controlada y metodo para fabricarlo.
|
|
ATE524446T1
(de)
|
2006-12-20 |
2011-09-15 |
Boehringer Ingelheim Int |
Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität
|
|
WO2008116890A2
(en)
|
2007-03-28 |
2008-10-02 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
|
|
US8486452B2
(en)
|
2007-07-20 |
2013-07-16 |
Mylan Pharmaceuticals Inc. |
Stabilized tolterodine tartrate formulations
|
|
CL2008002693A1
(es)
|
2007-09-12 |
2009-10-16 |
Boehringer Ingelheim Int |
Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
|
|
CA2686480A1
(en)
|
2008-12-15 |
2010-06-15 |
Boehringer Ingelheim International Gmbh |
New salts
|